Christine Koulis

Christine Koulis

UNVERIFIED PROFILE

Are you Christine Koulis?   Register this Author

Register author
Christine Koulis

Christine Koulis

Publications by authors named "Christine Koulis"

Are you Christine Koulis?   Register this Author

8Publications

133Reads

36Profile Views

The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis.

Diabetologia 2016 08 11;59(8):1778-90. Epub 2016 May 11.

JDRF Danielle Alberti Memorial Centre for Diabetic Complications, Diabetic Complications Division, Baker IDI Heart and Diabetes Research Institute, 75 Commercial Road, P. O. Box 6492, Melbourne, VIC, 3004, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00125-016-3977-5DOI Listing
August 2016

AT2R agonist, compound 21, is reno-protective against type 1 diabetic nephropathy.

Hypertension 2015 May 16;65(5):1073-81. Epub 2015 Mar 16.

From the Diabetic Complications Division, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia (C.K., B.S.M.C., M.M., V.T.-B., M.C.T., M.E.C., K.A.J.-D., T.J.A.); the Department of Medicine, Monash University, Monash, Australia (M.C.T., M.E.C., K.A.J.-D., T.J.A.); IMM-Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense. Denmark (U.M.S.); and CARIM-School of Cardiovascular Diseases, Maastricht University, Maastricht, Netherlands (T.U.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/HYPERTENSIONAHA.115.05204DOI Listing
May 2015

Protective role for Toll-like receptor-9 in the development of atherosclerosis in apolipoprotein E-deficient mice.

Arterioscler Thromb Vasc Biol 2014 Mar 16;34(3):516-25. Epub 2014 Jan 16.

From the Department of Cell Biology & Atherosclerosis (C.K., Y.C.C., C.H., I.A., T.S.K., C.T., A.B., K.P., A.A.) and Department of Diabetic Complications (C.K., T.A., K.J.-D.), Heart and Diabetes Institute, Melbourne, Victoria, Australia; Department of Cardiology and Angiology I, Heart Centre Freiburg University, Freiburg, Germany (I.A.); Molecular Cell Biology Division, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia (M.J.S.); Laboratory of Host Defense, WPI Immunology Frontier Research Centre, Osaka University, Osaka, Japan (S.A.); and Department of Immunology, Monash University, Melbourne, Victoria, Australia (A.B., K.P., A.A.).

View Article

Download full-text PDF

Source
https://www.ahajournals.org/doi/10.1161/ATVBAHA.113.302407
Publisher Site
http://dx.doi.org/10.1161/ATVBAHA.113.302407DOI Listing
March 2014

Novel pathways and therapies in experimental diabetic atherosclerosis.

Expert Rev Cardiovasc Ther 2012 Mar;10(3):323-35

Diabetic Complications Group, Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/erc.12.13DOI Listing
March 2012

STIM1: a new therapeutic target in occlusive vascular disease?

Cardiovasc Res 2009 Mar 15;81(4):627-8. Epub 2009 Jan 15.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/cvr/cvp018DOI Listing
March 2009